Oilon: HVAC Industry Leader Goes With Environmentally Friendly Heat Pump Technology Developed in Finland
16.12.2021 10:00:00 EET | Business Wire | Press release
Oilon, the Finnish energy and environmental technology company, has signed a collaboration agreement with Trane®, a leading global provider of indoor comfort solutions and services and a brand of Trane Technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211215005409/en/
In November 2021, Oilon opened a new plant for manufacturing industrial heat pumps in Kokkola (Finland). The capacity of the new plant is four times higher than the existing one. (Photo: Business Wire)
As part of the agreement, Trane will offer in Europe the Trane Exergy Series heat pumps designed and manufactured in collaboration with Oilon. The Exergy Series units deliver heating capacity of up to 120 degrees Celsius and can replace oil and gas boilers in industrial process, buildings and district heating applications.
– "Hardly any companies have managed to develop environmentally friendly technologies capable of such high temperatures. Cooperation with one of the world's largest players in the industry will help us to promote this sustainable technology more and more widely," says Martti Kukkola, Chief Business Officer for Oilon's Industrial Heat Pumps and Chillers.
Heat pumps are indeed regarded as one of the most significant means of producing fossil-free energy in the process industry and energy companies.
– "The agreement is a great reward for the long-term work we have done for over a decade to develop carbon-neutral energy production technologies", Kukkola adds.
In November 2021, Oilon opened a new plant for manufacturing industrial heat pumps in Kokkola (Finland). The capacity of the new plant is four times higher than the existing one.
Moreover, it will further accelerate the development of the industrial heat pump business, where Oilon has seen a notable expansion in recent years: deliveries grew significant. At present, the greatest demand comes from the European market, the needs of which are met by cooperation with Trane.
– "We have aggressive growth targets in industrial heat pumps, which are expected to become Oilon's core business in a few years' time. With such prospects, the capacity of the new plant will only be enough for a couple of years," Kukkola reckons.
Contact:
Oilon is a family-owned, global energy and environmental technology company, founded in 1961. Oilon specialises in energy and environmental technology with focus on industrial heat pumps and chillers, ground source heat pumps, and burners and combustion systems. Oilon conducts continuous product development to improve energy efficiency, reduce emissions and create solutions based on renewable energy sources.
Oilon has a of €70 million turnover and employs 380 people. The company has production facilities in Finland, the United States, China and Russia, as well as sales offices in Brazil and Germany. Furthermore, Oilon runs an international sales network of 70 dealers.
About Trane
Trane – by Trane Technologies (NYSE: TT), a global climate innovator – creates comfortable, energy efficient indoor environments for commercial and residential applications. For more information, please visit www.trane.eu or www.tranetechnologies.com .
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211215005409/en/
Contact information
Martti Kukkola – Chief Business Officer
Industrial heat pumps and chillers
Oilon Oy
Tel. +358 3 85 761, Mob. +358 400 312 060
martti.kukkola@oilon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom